Skip to main content
Caplight Logo









AnHorn Medicines

AnHorn Medicines

Private
TaipeiHealthcare & Life Scienceshttps://www.anhornmed.com/

Last Round

Series A

Apr 25, 2023

Total Funding Raised

$10M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

AnHorn Medicines is a clinical-stage biotechnology company developing first-in-class and best-in-class drugs for cancers, autoimmune diseases, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small molecule drug discoveryAI drug discoveryclinical-stage biotechtechbioallosteric modulationnon-small cell lung cancerNSCLConcologyEGFR inhibitorsbrain-penetrant drugstyrosine kinase inhibitorTKIdrug resistanceprecision medicinegenerative AI drug discoverybrain metastasisbiotech out-licensingneurodegenerative diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AnHorn Medicines Comparables

Compare AnHorn Medicines with similar companies based on industry and business-model similarity.

AnHorn Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allorion Therapeutics
83%
Black Diamond Therapeutics
77%
C4 Therapeutics
74%

AnHorn Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 25, 2023

Key People

Founding team and executive leadership

Chu-Chiang Lin

Chief Executive Officer

Executive Team

AnHorn Medicines Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 17, 2.3x the trailing average.

  • Mar 2, 2026

    Monthly visitors increased 46% MoM, reaching 1.2K.

AnHorn Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AnHorn Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AnHorn Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersTaipei
Employee Range13
Year Founded2017
Last FundingApr 25, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?